A detailed history of Ibex Wealth Advisors transactions in Eli Lilly & CO stock. As of the latest transaction made, Ibex Wealth Advisors holds 11,635 shares of LLY stock, worth $9.44 Million. This represents 1.11% of its overall portfolio holdings.

Number of Shares
11,635
Holding current value
$9.44 Million
% of portfolio
1.11%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 23, 2025

BUY
$727.2 - $932.06 $8.46 Million - $10.8 Million
11,635 New
11,635 $8.98 Million
Q2 2024

Aug 06, 2024

BUY
$724.87 - $909.04 $3.92 Million - $4.92 Million
5,408 Added 84.71%
11,792 $10.7 Million
Q1 2024

Apr 18, 2024

BUY
$592.2 - $792.28 $3.77 Million - $5.05 Million
6,374 Added 63740.0%
6,384 $2.34 Million
Q4 2023

Jan 29, 2024

SELL
$525.19 - $619.13 $4.7 Million - $5.55 Million
-8,958 Reduced 99.89%
10 $5.74 Million
Q3 2023

Nov 07, 2023

BUY
$434.7 - $599.3 $3.9 Million - $5.37 Million
8,968 New
8,968 $4.82 Million
Q4 2022

Feb 06, 2023

BUY
$321.55 - $374.67 $53,377 - $62,195
166 Added 2.67%
6,384 $2.34 Million
Q3 2022

Oct 31, 2022

SELL
$296.48 - $337.87 $13,638 - $15,542
-46 Reduced 0.73%
6,218 $2.01 Million
Q2 2022

Aug 16, 2022

SELL
$278.73 - $327.27 $32,053 - $37,636
-115 Reduced 1.8%
6,264 $2.03 Million
Q1 2022

May 16, 2022

BUY
$234.69 - $291.66 $1.5 Million - $1.86 Million
6,379 New
6,379 $1.83 Million
Q4 2021

Feb 22, 2022

SELL
$224.85 - $279.04 $8,544 - $10,603
-38 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$221.6 - $272.71 $8,420 - $10,362
38 New
38 $9,000
Q3 2019

Nov 12, 2019

SELL
$106.79 - $116.16 $4,805 - $5,227
-45 Closed
0 $0
Q2 2019

Jul 30, 2019

SELL
$110.79 - $129.32 $1.5 Million - $1.75 Million
-13,545 Reduced 99.67%
45 $4,000
Q1 2019

May 01, 2019

BUY
$111.31 - $131.02 $1.51 Million - $1.78 Million
13,590 New
13,590 $1.76 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $771B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Ibex Wealth Advisors Portfolio

Follow Ibex Wealth Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ibex Wealth Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Ibex Wealth Advisors with notifications on news.